Mucosal and systemic immune responses after a single intranasal dose of nanoparticle and spore-based subunit vaccines in mice with pre-existing lung mycobacterial immunity
Open Access
- 7 December 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1306449
Abstract
Tuberculosis (TB) is a major global health threat that claims more than one million lives annually. With a quarter of the global population harbouring latent TB, post-exposure vaccination aimed at high-risk populations that could develop active TB disease would be of great public health benefit. Mucosal vaccination is an attractive approach for a predominantly lung disease like TB because it elicits both local and systemic immunity. However, the immunological consequence of mucosal immunisation in the presence of existing lung immunity remains largely unexplored. Using a mycobacterial pre-exposure mouse model, we assessed whether pre-existing mucosal and systemic immune responses can be boosted and/or qualitatively altered by intranasal administration of spore- and nanoparticle-based subunit vaccines. Analysis of lung T cell responses revealed an increasing trend in the frequency of important CD4 and CD8 T cell subsets, and T effector memory cells with a Th1 cytokine (IFNγ and TNFα) signature among immunised mice. Additionally, significantly greater antigen specific Th1, Th17 and IL-10 responses, and antigen-induced T cell proliferation were seen from the spleens of immunised mice. Measurement of antigen-specific IgG and IgA from blood and bronchoalveolar lavage fluid also revealed enhanced systemic and local humoral immune responses among immunised animals. Lastly, peripheral blood mononuclear cells (PBMCs) obtained from the TB-endemic country of Mozambique show that individuals with LTBI showed significantly greater CD4 T cell reactivity to the vaccine candidate as compared to healthy controls. These results support further testing of Spore-FP1 and Nano-FP1 as post-exposure TB vaccines.Keywords
Funding Information
- European Commission (860325, 643558)
- Bill and Melinda Gates Foundation (INV-031830)
This publication has 62 references indexed in Scilit:
- Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1− IL-2–Secreting Central Memory CellsThe Journal of Immunology, 2013
- IFN-γ from CD4 T Cells Is Essential for Host Survival and Enhances CD8 T Cell Function during Mycobacterium tuberculosis InfectionThe Journal of Immunology, 2013
- Bronchoalveolar CD4+ T cell responses to respiratory antigens are impaired in HIV-infected adultsThorax, 2011
- The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementEuropean Respiratory Journal, 2010
- Response to Rv2628 latency antigen associates with cured tuberculosis and remote infectionEuropean Respiratory Journal, 2009
- T cells in mycobacterial infection and diseaseCurrent Opinion in Immunology, 2009
- IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challengeNature Immunology, 2007
- Identification and HLA Restriction of Naturally Derived Th1-Cell Epitopes from the SecretedMycobacterium tuberculosisAntigen 85B Recognized by Antigen-Specific Human CD4+T-Cell LinesInfection and Immunity, 2000
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- THE FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUEJournal of Experimental Medicine, 1956